Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373 · see citing works

The DNA Damage Response: Ten Years After

Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · see citing works

Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells

Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617 · see citing works

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · see citing works

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · see citing works

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works

Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks

Celeste, A., Fernandez-Capetillo, O., Kruhlak, M. J., Pilch, D. R., Staudt, D. W., Lee, A., Bonner, R. F., Bonner, W. M., & Nussenzweig, A. (2003) · Nature Cell Biology · doi:10.1038/ncb1004 · Cited by 989 · see citing works

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823 · see citing works

RAP80 Targets BRCA1 to Specific Ubiquitin Structures at DNA Damage Sites

Sobhian, B., Shao, G., Lilli, D. R., Culhane, A. C., Moreau, L. A., Xia, B., Livingston, D. M., & Greenberg, R. A. (2007) · Science · doi:10.1126/science.1139516 · Cited by 672 · see citing works

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666 · see citing works

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 595 · see citing works

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2820 · Cited by 585 · see citing works

Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks

Galanty, Y., Belotserkovskaya, R., Coates, J., Polo, S. E., Miller, K. M., & Jackson, S. P. (2009) · Nature · doi:10.1038/nature08657 · Cited by 520 · see citing works

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34588 · Cited by 519 · see citing works

Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp

Nagai, Y., Miyazawa, H., Huqun, Tanaka, T., Udagawa, K., Kato, M., Fukuyama, S., Yokote, A., Kobayashi, K., Kanazawa, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0331 · Cited by 503 · see citing works

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457 · see citing works

The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress

Morris, J. R., Boutell, C., Epple, M., Densham, R. M., Weekes, D. B., Alamshah, A., Butler, L. R., Galanty, Y., Pangon, L., Kiuchi, T., et al. (2009) · Nature · doi:10.1038/nature08593 · Cited by 434 · see citing works

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., & Harkin, D. P. (2003) · PubMed · Cited by 400 · see citing works

Chaperoning Histones during DNA Replication and Repair

Ransom, M., Dennehey, B. K., & Tyler, J. K. (2010) · Cell · doi:10.1016/j.cell.2010.01.004 · Cited by 345 · see citing works

Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs

Bindra, R. S., Gibson, S. L., Meng, A. X., Westermark, U., Jasin, M., Pierce, A. J., Bristow, R. G., Classon, M. K., & Glazer, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2119 · Cited by 334 · see citing works

Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance

Chan, N. H. L., Koritzinsky, M., Zhao, H. W., Bindra, R. S., Glazer, P. M., Powell, S. N., Belmaaza, A., Wouters, B. G., & Bristow, R. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5472 · Cited by 328 · see citing works

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

Tarón, M., Rosell, R., Felip, E., Méndez, P., Souglakos, J., Ronco, M. S., Queralt, C., Majo, J., Sánchez, J. M., Sánchez, J. J., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh260 · Cited by 308 · see citing works

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G. A., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 303 · see citing works

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

Mahadevan, D., Cooke, L. S., Riley, C., Swart, R. E., Simons, B. W., Croce, K. D., Wisner, L., Iorio, M. V., Shakalya, K., Garewal, H. S., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210173 · Cited by 283 · see citing works

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

Kuang, Y., Rogers, A. M., Yeap, B. Y., Wang, L., Makrigiorgos, M. G., Vetrand, K., Thiede, S., Distel, R. J., & Janne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 230 · see citing works

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.Preprint

Oliver, T., Mercer, K. L., Sayles, L., Burke, J., Mendus, D., Lovejoy, K. S., Cheng, M., Subramanian, A., Mu, D., Powers, S., et al. (2010) · Genes & Development · doi:10.1101/gad.1897010 · Cited by 220 · see citing works

Non–Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation

Das, A. K., Sato, M., Story, M. D., Peyton, M., Graves, R., Redpath, S., Girard, L., Gazdar, A. F., Shay, J. W., Minna, J. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2627 · Cited by 217 · see citing works

211 BRCA1 functions as a differential modulator of chemotherapy induced apoptosis

Quinn, J. E., Kennedy, R. D., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(04)80219-2 · Cited by 215 · see citing works

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130

Hegan, D. C., Lü, Y., Stachelek, G. C., Crosby, M. E., Bindra, R. S., & Glazer, P. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904783107 · Cited by 209 · see citing works

BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

Quinn, J. E., James, C. R., Stewart, G. E., Mulligan, J. M., White, P., Chang, G. K. F., Mullan, P. B., Johnston, P. G., Wilson, R. H., & Harkin, D. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1083 · Cited by 208 · see citing works

Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line

Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 193 · see citing works

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

Rosell, R., Perez‐Roca, L., Sánchez, J. J., Cobo, M., Morán, T., CHAIB-OUKADOUR, I., Provencio, M., Dómine, M., Sala, M. Á., Jiménez, U., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005133 · Cited by 160 · see citing works

Somatic Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) Abrogate EGFR-Mediated Radioprotection in Non–Small Cell Lung Carcinoma

Das, A. K., Chen, B. P., Story, M. D., Sato, M., Minna, J. D., Chen, D. J., & Nirodi, C. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0242 · Cited by 159 · see citing works

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients

Boukovinas, I., Papadaki, C., Méndez, P., Tarón, M., Mavroudis, D., Koutsopoulos, A. V., Sanchez-Ronco, M., Sánchez, J. J., Trypaki, M., Staphopoulos, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003695 · Cited by 125 · see citing works

Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells

Li, L., Wang, H., Yang, E. S.-H., Arteaga, C. L., & Xia, F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1127 · Cited by 123 · see citing works

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells

Molina‐Vila, M. Á., Bertrán-Alamillo, J., Reguart, N., Tarón, M., Castellà, E., Llatjós, M., Costa, C., Mayo, C., Pradas, A., Queralt, C., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f579 · Cited by 112 · see citing works

MRE11-RAD50-NBS1 Complex Dictates DNA Repair Independent of H2AX

Yuan, J., & Chen, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.078436 · Cited by 111 · see citing works

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

Mack, P. C., Holland, W. S., Burich, R. A., Sangha, R. S., Solis, L. J., Li, Y., Beckett, L. A., Lara, P. N., Davies, A. M., & Gandara, D. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181bbf239 · Cited by 66 · see citing works

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

Vila, M. M., Cirauqui, B., Castellà, E., Tapia, G., Costa, C., Giménez-Capitán, A. A., Barnadas, A., Ronco, M. S., Benlloch, S., Tarón, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009499 · Cited by 46 · see citing works

A PIAS-ed view of DNA double strand break repair focuses on SUMO

Zlatanou, A., & Stewart, G. S. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.02.003 · Cited by 13 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,316 · see citing works

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,305 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Non–Small Cell Lung Cancer

_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737 · see citing works

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 742 · see citing works

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593 · see citing works

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

Lee, C. K., Brown, C. S. B., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E. H., Ho, J., Chu, D., Zaatar, A., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt072 · Cited by 505 · see citing works

Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499 · see citing works

Non–Small Cell Lung Cancer, Version 6.2015

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0071 · Cited by 478 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467 · see citing works

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463 · see citing works

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

Yang, J. C., Shih, J., Su, W., Hsia, T., Tsai, C., Ou, S. I., Yu, C., Chang, G., Ho, C., Sequist, L. V. D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70086-4 · Cited by 410 · see citing works

EGFR signaling pathway as therapeutic target in human cancers

Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 372 · see citing works

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 355 · see citing works

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Remón, J., Steuer, C. E., Ramalingam, S. S., & Felip, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx704 · Cited by 326 · see citing works

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 311 · see citing works

Genetics and biomarkers in personalisation of lung cancer treatment

Rosell, R., Bivona, T. G., & Karachaliou, N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61715-8 · Cited by 304 · see citing works

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0054 · Cited by 287 · see citing works

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285 · see citing works

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259 · see citing works

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 267 · see citing works

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

Wang, Y.-Q., Wang, P., Wang, Y.-T., Yang, G., Zhang, A., & Miao, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00055 · Cited by 248 · see citing works

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Greenhalgh, J., Dwan, K. M., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Jain, P., & Green, J. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub2 · Cited by 244 · see citing works

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 233 · see citing works

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229 · see citing works

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Gelatti, A., Drilon, A. E. D. C., & Santini, F. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.017 · Cited by 220 · see citing works

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2151 · Cited by 216 · see citing works

Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients

Castellanos-Rizaldos, E., Grimm, D. G., Tadigotla, V. R., Hurley, J. D., Healy, J., Neal, P. L., Sher, M., Venkatesan, R., Karlovich, C., Raponi, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3369 · Cited by 218 · see citing works

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

CHAIB-OUKADOUR, I., Karachaliou, N., Pilotto, S., Servat, J. C., Cai, X., Li, X., Drozdowskyj, A., Codony, C., Yang, J. E., Hu, C., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx014 · Cited by 210 · see citing works

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt573 · Cited by 206 · see citing works

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201 · see citing works

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

Shi, Y., Li, J., Zhang, S., Wang, M., Yang, S., Li, N., Wu, G., Liu, W., Liao, G., Cai, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143515 · Cited by 196 · see citing works

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

Sørensen, B. S., Wu, L., Wei, W., Tsai, J., Weber, B., Nexø, E., & Meldgaard, P. (2014) · Cancer · doi:10.1002/cncr.28964 · Cited by 194 · see citing works

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial

Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30129-7 · Cited by 182 · see citing works

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gascó, A., Mayo‐de‐las‐Casas, C., Sanchez-Ronco, M., Pujantell-Pastor, L., Bonanno, L., Favaretto, A. G., Cardona, A. F., Vergnenégre, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2391 · Cited by 181 · see citing works

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 176 · see citing works

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H. ‐., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0482-y · Cited by 178 · see citing works

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Jimeno, A., Weiss, G. J., Miller, W. H., Gettinger, S. N., Eigl, B. J., Chang, A. L. S., Dunbar, J., Devens, S., Faia, K., Skliris, G. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3654 · Cited by 171 · see citing works

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Jacobsen, K., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony, C., Codony‐Servat, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00450-6 · Cited by 159 · see citing works

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158 · see citing works

Personalized medicine in lung cancer: what we need to know

Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 160 · see citing works

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 150 · see citing works

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 141 · see citing works

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 135 · see citing works

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

Ou, S. I., Young, L., Schrock, A. B., Johnson, A., Klempner, S. J., Zhu, V. W., Miller, V. A., & Ali, S. M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.119 · Cited by 133 · see citing works

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 129 · see citing works

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110780 · Cited by 129 · see citing works

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

Oxnard, G. R., Miller, V. A., Robson, M. E., Azzoli, C. G., Pao, W. J., Ladanyi, M., & Arcila, M. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318250ed9d · Cited by 128 · see citing works

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 127 · see citing works

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121 · see citing works

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 119 · see citing works

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

Sun, J., Ahn, M., Choi, Y., Ahn, J. S., & Park, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.023 · Cited by 118 · see citing works

Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

Fujita, Y., Suda, K., Kimura, H., Matsumoto, K., Arao, T., Nagai, T., Saijo, N., Yatabe, Y., Mitsudomi, T., & Nishio, K. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182653d7f · Cited by 117 · see citing works

Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

Querings, S., Altmüller, J., Ansén, S., Zander, T., Seidel, D., Gabler, F., Peifer, M., Markert, E., STEMSHORN, K. C., Timmermann, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019601 · Cited by 115 · see citing works

Droplet-Based Digital PCR

Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 111 · see citing works

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104 · see citing works

EGFR mutations in lung cancer: from tissue testing to liquid biopsy

Fenizia, F., Luca, A. D., Pasquale, R., Sacco, A., Forgione, L., Lambiase, M., Iannaccone, A., Chicchinelli, N., Franco, R., Rossi, A., et al. (2015) · Future Oncology · doi:10.2217/fon.15.23 · Cited by 94 · see citing works

Common <i>EGFR</i> -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors

Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91 · see citing works

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

Reguart, N., Rosell, R., Cardenal, F., Cardona, A. F., Isla, D., Palmero, R., Morán, T., Rolfo, C. D., Pallarès, M. C., Insa, A., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.02.011 · Cited by 87 · see citing works

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

Zhou, C., & Yao, L. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.002 · Cited by 87 · see citing works

High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

Ye, X., Zhu, Z.-Z., Zhong, L., Lu, Y., Sun, Y., Yin, X., Yang, Z., Zhu, G., & Ji, Q. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f691f · Cited by 79 · see citing works

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

Lohinai, Z., Hoda, M. A., Fábián, K., Ostoros, G., Rásó, E., Barbai, T., Tı́már, J., Kovalszky, I., Cserepes, M., Rózsás, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000492 · Cited by 81 · see citing works

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80 · see citing works

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Lin, L., & Bivona, T. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817297 · Cited by 80 · see citing works

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

Sakai, K., Horiike, A., Irwin, D. L., Kudo, K., Fujita, Y., Tanimoto, A., Sakatani, T., Saito, R., Kaburaki, K., Yanagitani, N., et al. (2013) · Cancer Science · doi:10.1111/cas.12211 · Cited by 78 · see citing works

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

Dienstmann, R., Dosso, S. D., Felip, E., & Tabernero, J. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.009 · Cited by 75 · see citing works

EGFR T790M resistance mutation in non small-cell lung carcinoma

Denis, M. G., Vallée, A., & Théoleyre, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.039 · Cited by 75 · see citing works

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

Wang, Z., & Fang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s69690 · Cited by 75 · see citing works

Current Approaches in NSCLC Targeting K-RAS and EGFR

Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74 · see citing works

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

Kuiper, J. L., Hashemi, S. M. S., Thunnissen, E., Snijders, P. J. F., Grünberg, K., Bloemena, E., Sie, D., Postmus, P. E., Heideman, D. A. M., & Smit, E. F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.372 · Cited by 73 · see citing works

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Li, X., Ren, R., Ren, S., Chen, X., Cai, W., Zhou, F., Zhang, Y., Su, C., Zhao, C., Li, J., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.04.006 · Cited by 73 · see citing works

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub3 · Cited by 73 · see citing works

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

Ji, W., Choi, C., Rho, J. K., Jang, S. J., Park, Y. S., Chun, S., Kim, W. S., Lee, J., Kim, S., Lee, D. H., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-606 · Cited by 72 · see citing works

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma

Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3727 · Cited by 73 · see citing works

Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer

Chen, M., Xu, Y., Zhao, J., Zhong, W., Zhang, L., Bi, Y., & Wang, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.023 · Cited by 70 · see citing works

Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis

Chen, L.-Y., Molina-Vila, M. A., Ruan, S.-Y., Su, K.-Y., Liao, W.-Y., Yu, K.-L., Ho, C.-C., Shih, J.-Y., Yu, C.-J., Yang, J. C.-H., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.019 · Cited by 67 · see citing works

Tumor Burden is Predictive of Survival in Patients With Non–Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib

Park, J. H., Kim, T. M., Keam, B., Jeon, Y. K., Lee, S., Kim, D., Chung, D. H., Kim, Y. T., Kim, Y. W., & Heo, D. S. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.10.007 · Cited by 67 · see citing works

Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer

Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 65 · see citing works

Comprehensive molecular screening: from the RT-PCR to the RNA-seq.

Costa, C., Giménez-Capitán, A. A., Karachaliou, N., & Rosell, R. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.05 · Cited by 66 · see citing works

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66 · see citing works

Mechanisms of resistance to EGFR targeted therapies

Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 65 · see citing works

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib

Takeda, M., Okamoto, I., & Nakagawa, K. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000053 · Cited by 65 · see citing works

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Karachaliou, N., Codony‐Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gervais, R., et al. (2015) · Scientific Reports · doi:10.1038/srep17499 · Cited by 64 · see citing works

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64 · see citing works

Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective

Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.005 · Cited by 64 · see citing works

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling

WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 63 · see citing works

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib

Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 62 · see citing works

The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients

Couck, M., van Brummelen, D., Schallier, D. C. C., Grève, J. D., & Gidron, Y. (2013) · Oncology Reports · doi:10.3892/or.2013.2725 · Cited by 62 · see citing works

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer

Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00190 · Cited by 57 · see citing works

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Riediger, A. L., Dietz, S., Schirmer, U. B., Meister, M. A., Heinzmann-Groth, I., Schneider, M. A., Muley, T., Thomas, M., & Sültmann, H. (2016) · Scientific Reports · doi:10.1038/srep33505 · Cited by 58 · see citing works

Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma

Ren, S., Chen, X., Kuang, P., Zheng, L.-M., Su, C., Li, J., Li, B., Wang, Y., Liu, L., Hu, Q., et al. (2012) · Cancer · doi:10.1002/cncr.27603 · Cited by 57 · see citing works

STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics

Zulkifli, A., Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.010 · Cited by 57 · see citing works

Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update

Ahsan, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_7 · Cited by 56 · see citing works

Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs

Liu, Y., Sun, L., Xiong, Z., Sun, X., Zhang, S., Ma, J., & Han, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133082 · Cited by 54 · see citing works

Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients

Yang, M., Shan, B., Li, Q., Song, X., Cai, J., Deng, J., Zhang, L., 杜镇建, Lu, J., Chen, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27813 · Cited by 53 · see citing works

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Tartarone, A., & Lerose, R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815587820 · Cited by 53 · see citing works

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Codony, C., Codony‐Servat, J., Karachaliou, N., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Ramírez, J. L., Gil, M. D. L. L., Solca, F., Bivona, T. G., & Rosell, R. (2017) · Oncotarget · doi:10.18632/oncotarget.17625 · Cited by 50 · see citing works

EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing

Lettig, L., Sahnane, N., Pepe, F., Cerutti, R., Albeni, C., Franzi, F., Veronesi, G., Ogliari, F. R., Pastore, A., Tuzi, A., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.18 · Cited by 49 · see citing works

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

Rosell, R., Molina, M. A., Costa, C., Tarón, M., Bertrán-Alamillo, J., Mayo, C., Benlloch, S., Morán, T., Cardenal, F., & Porta, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7514 · Cited by 14 · see citing works

BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Karachaliou, N., Costa, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Mayo, C., Massutí, B., Majem, M., Carcereny, E., Morán, T., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db621 · Cited by 19 · see citing works

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229 · see citing works

Abstract 1727: Correlation between BRCA1 and LMO4 mRNA expression levels in Erlotinib-treated non small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations

Costa, C., Giménez-Capitán, A. A., Benlloch, S., Tarón, M., Jimeno, J. M., Viteri, S., Gascó, A., Camps, C., Carcereny, E., Massutí, B., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-1727

Abstract 4112: De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy

Rosell, R., Molina‐Vila, M. Á., Sánchez, J. J., Tarón, M., Benlloch, S., Morán, T., Carcereny, E., Cardenal, F., Massutí, B., & Magrí, I. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4112 · Cited by 1 · see citing works